Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27869033 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL27649068 | 0.81 | ALOX15 (0.36) | ALOX15SLC1A2SLC1A1 | |
| SCHEMBL29265358 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL16666609 | 0.79 | — | — | |
| SCHEMBL27554174 | 0.78 | TSHR (0.33) | ALOX15 | |
| SCHEMBL1763468 | 0.78 | ALOX15 (0.31) | ALOX15 | |
| SCHEMBL1020071 | 0.77 | ALDH1A1 (0.32) | ALOX15EP300HIF1ACREBBP | |
| SCHEMBL19392125 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL4079599 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL2192555 | 0.75 | TSHR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | claimed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | claimed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | claimed |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-10138270-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2018-11-27 | — | — | US | claimed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | claimed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | claimed |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2016-12-29 | — | — | US | claimed |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | US | claimed |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | US | claimed |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | claimed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | claimed |
| EP-2079756-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | Cara Therapeutics, Inc. (US) | 2009-07-22 | — | — | EP | claimed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | claimed |
| EP-2064228-A2 | SYNTHETIC PEPTIDE AMIDES | Cara Therapeutics, Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | claimed |
| WO-2008060552-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| WO-2008057608-A2 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | ALOX15 329/4885SLC1A2 914/4885SLC1A1 1688/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | ALOX15 329/4885SLC1A2 914/4885SLC1A1 1688/4885 |
| US-10138270-B2 | Synthetic peptide amides | VIP, OPRK1, OPRL1 | ALOX15 1149/4885SLC1A2 162/4885SLC1A1 151/4885 |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | ALOX15 524/4885SLC1A2 232/4885SLC1A1 198/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | ALOX15 743/4885SLC1A2 151/4885SLC1A1 176/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | ALOX15 887/4885SLC1A2 144/4885SLC1A1 161/4885 |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | ALOX15 887/4885SLC1A2 144/4885SLC1A1 161/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | ALOX15 1149/4885SLC1A2 162/4885SLC1A1 151/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | ALOX15 1665/4885SLC1A2 290/4885SLC1A1 262/4885 |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | ALOX15 1149/4885SLC1A2 162/4885SLC1A1 151/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | ALOX15 329/4885SLC1A2 914/4885SLC1A1 1688/4885 |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | ALOX15 329/4885SLC1A2 914/4885SLC1A1 1688/4885 |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | ALOX15 2316/4885SLC1A2 972/4885SLC1A1 308/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | ALOX15 524/4885SLC1A2 232/4885SLC1A1 198/4885 |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | ALOX15 524/4885SLC1A2 232/4885SLC1A1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.